Pharmacist Medication Insights: Margetuximab for Metastatic HER2-Positive Breast Cancer
July 13th 2021Margetuximab-cmkb (Margenza) was approved in December 2020 in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have previously received 2 or more anti-HER2 regimens, at least one of which for metastatic disease.
Highlights of the Patient Experience with Tavalisse
July 12th 2021Pharmacy Times spoke with Bhavesh Shah, associate chief pharmacy officer for hematology/oncology, about his session titled Stand Strong Against Platelet Destruction With Tavalisse®: A Patient’s ITP Treatment Journey, which he presented at the 2021 ATOPP Summit.
Impact of FDA Approval of Infigratinib on the Field of Cholangiocarcinoma Treatment
July 9th 2021Milind Javle, PhD, professor of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center, discussed the importance of the FDA’s expedited approval process for infigratinib in the treatment of previously treated locally advanced or metastatic cholangiocarcinoma.
New Digital Tool Provides Resources for Patients With Small Cell Lung Cancer and Their Caregivers
July 9th 2021In an interview with Pharmacy Times® and Directions in Oncology Pharmacy®, Abizer Gaslightwala, vice president and head of the U.S. Hematology and Oncology division at Jazz Pharmaceuticals discusses the company’s new digital resource, Nothing Small About It.
Adverse Events Among Patients With Type 2 Diabetes, COVID-19 Treated With Dapagliflozin
July 8th 2021Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed what some of the adverse events experienced by patients were, and how patients were able to handle them.